Experience of using genetic engineering biological therapy in a patient with psoriasis and chronic renal failure under hemodialysis.

Psoriasis is a chronic immune-associated disease of a multifactorial nature. The prevalence of the disease, chronic course, impact on the patient’s quality of life, as well as the connection with the risk of progression of various comorbid conditions necessitate a detailed and comprehensive approach to the treatment of this group of patients. There has been a correlation of psoriasis with the risk of many comorbid pathologies, such as psoriatic arthritis, metabolic syndrome, liver and kidney disorders. There is evidence in the literature about the relationship between chronic renal failure and psoriasis, but the data are limited and require further study. According to Russian clinical guidelines, for moderate and severe forms of psoriasis, the prescription of systemic immunosuppressive therapy, targeted and genetically engineered biological drugs is indicated. Of particular interest is the determination of management tactics and selection of therapy if a patient with psoriasis has concomitant pathology due to the lack of a sufficient number of safety studies taking into account this or that comorbidity. We present the data known to us from a literature review on the stated problem. In view of the need to expand the data of real clinical practice on the possible risks of managing patients with psoriasis, we present a description of our own clinical experience of using the inhibitor interleukin 17A in a patient with chronic renal failure and hemodialysis.